Work

Assessing the Therapeutic Outcomes and Safety of Generic vs Branded Teneligliptin in Type-2 Diabetic Patients: A Lipid Profile Perspective

Year: 2024

Type: article

Abstract: Background: Teneligliptin is a DPP-4 inhibitor widely used in the management of Type-2 Diabetes Mellitus (T2DM) to improve glycemic control. While both branded and generic versions are available, there is limited data comparing their therapeutic efficacy and safety, particularly concerning lipid profiles and renal function. This study aimed to compare the therapeutic outcomes and safety profiles of branded versus generic Teneligliptin in managing glycemic control and lipid profiles in patients with Type-2 Diabetes Mellitus (T2DM). Methods: A total of 200 patients with T2DM were randomized to receive either branded or generic Teneligliptin for six months. Efficacy was assessed through changes in HBA1C, fasting blood sugar (FBS), lipid profiles (cholesterol), and serum creatinine levels at baseline, 3 months, and 6 months. Results: Both branded and generic formulations effectively reduced HBA1C levels from 7.50% to 6.40% and 7.90% to 6.50%, respectively, after 6 months. The overall reduction was slightly higher in the branded group (1.10% vs. 1.40% in the generic group). FBS showed a comparable reduction, with branded Teneligliptin lowering FBS from 170 mg/dl to 166 mg/dl and the generic formulation from 178 mg/dl to 165 mg/dl. Cholesterol levels were reduced in both groups, with branded Teneligliptin showing a more significant decrease (197 mg/dl to 175 mg/dl) compared to the generic (199 mg/dl to 178 mg/dl). Serum creatinine levels rose slightly in both groups, with the branded formulation showing a greater increase (0.82 mg/dl to 0.98 mg/dl) than the generic (0.60 mg/dl to 0.86 mg/dl), though no significant renal impairment was noted. Conclusion: Both branded and generic Teneligliptin are effective in improving glycemic control and lipid profiles in T2DM patients. However, the branded formulation demonstrated a marginally better effect on lipid management, while both formulations showed similar safety profiles.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.14036827

Authors: Ananthoju Viswasanthi, Kurli Sankar, P. Satya Gopal, Nidanapu Ravi Prasad

Institutions: Guntur Medical College, GSL Medical College & General Hospital, Siddhartha Medical College

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6911791552